NCT00278382View on ClinicalTrials.gov

Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

December 31, 2007

Conditions
Anaplastic Large Cell LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Mantle Cell Lymphoma
Interventions
DRUG

sorafenib tosylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

21201-1595

University of Maryland Greenebaum Cancer Center, Baltimore

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00278382 - Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter